ARGOS THERAPEUT (ARGS) Downgraded by Zacks to NEUTRAL

Zacks Zacks Investment Research downgraded shares of ARGOS THERAPEUT (ARGS) from N/A to NEUTRAL on August 27, 2014, with a target price of $9.00.

Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on ARGOS THERAPEUT (ARGS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply